Precision Medicine in Oncology

Understanding these genetic variants discovered through sequencing efforts is key to further progress in clinical genetics.

The Quality Cancer Care Alliance is focusing on 2 major topics: value-based care and innovation, and precision oncology is the intersection of those 2 issues, said Sibel Blau, MD.

Researchers conducting broad next-generation sequencing discovered more actionable variants in patients and families than they would have otherwise; they did so by using a universal approach, rather than sticking with clinical guidelines.

The FDA has approved new indications for Foundation Medicine's liquid biopsy assay and also its tissue-based companion diagnostic for solid tumors.

The study describes how RNA sequencing and DNA sequencing for selected genes were performed simultaneously to evaluate gene expression and alterations in order to predict tumor origin.

The launch comes as major cancer research organizations are calling for ways to increase diversity in clinical trials.

A recent analysis illustrated how a combination of different genomic approaches discovered actionable alterations in 44% of patients with metastatic breast cancer.

The researchers, from a medical genetics firm, said the findings illustrate the usefulness of germline analysis for the right patient.

Blythe Adamson, PhD, MPH, of Flatiron Health, discusses study results she presented at the annual American Society of Clinical Oncology meeting on the use of immune checkpoint inhibitors in end-of-life care

Next-generation sequencing (NGS) of cell-free DNA (cfDNA) may improve diagnostic testing in advanced lung cancer.

Andre Goy, MD, of John Theurer Cancer Center, discussed what we’ve learned from existing chimeric antigen receptor T (CAR T)-cell therapies in managing cytokine responses.

The opportunity that precision medicine presents in the field of oncology will be further discussed during this year’s Patient-Centered Oncology Care® 2020 virtual meeting.

Having biomarker-driven solutions in prostate cancer is important, because they have been lacking.

A new analysis of ADAURA data shows osimertinib cuts the risk of brain metastases or death by 82% compared with placebo in certain early-stage patients with NSCLC.

If approved, FoundationOne's CDx would be used to identify patients with non–small cell lung cancer (NSCLC) who are eligible for mobocertinib or brigatinib.

The research spotlights the diverse landscape of pediatric cancer types harboring 2 types of genomic alterations.

Pralsetinib (Gavreto), developed by Blueprint Medicines, received accelerated approval. Thermo Fisher Scientific's Oncomine Dx Target Test received premarket approval as a companion diagnostic to identify patients who are candidates for the once-daily oral RET-targeted therapy.

AstraZeneca's phase 3 trial of a coronavirus disease 2019 (COVID-19) vaccine has been temporarily stopped; the Sturgis Motorcycle Rally may have led to over 250,000 COVID-19 cases; a potential treatment for breast cancer may not be effective.

New findings indicate that relying on circulating tumor DNA (ctDNA) and tissue DNA tests are complementary measures that can better match patients with biliary tract cancer with precise therapies.

Combining chimeric antigen receptor (CAR) T-cell therapy and an oncolytic virus were more potent against solid tumors than CAR T-cell therapy alone in mouse models of cancer.

Liquid CDX, a blood test, analyzes more than 300 genes and genomic signatures across all solid tumors.

From the Editor-in-Chief, Evidence-Based Oncology, August 2020.

An agreement will tap Caris Life Sciences' next-generation sequencing technology to identify patients for Merus’ phase 1/2 eNRGy trial.

Oncology drug costs affect those entering into risk-based arrangements, and these groups must rethink their approach to evaluating risk.

Better technology is rekindling the promise of DNA medicines in oncology, including the treatment of glioblastoma.